These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23701880)

  • 1. Metabolic syndrome as a peculiar target for management of prostate cancer patients.
    Conteduca V; Di Lorenzo G; Bozza G; Ardito R; Aieta M
    Clin Genitourin Cancer; 2013 Sep; 11(3):211-20. PubMed ID: 23701880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin: taking away the candy for cancer?
    Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
    Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer?
    Aggarwal RR; Ryan CJ; Chan JM
    Urol Oncol; 2013 Jul; 31(5):522-30. PubMed ID: 21658978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a combination of rhGH and metformin on adiponectin levels in patients with metabolic syndrome.
    Herrmann BL; Saller B; Stratmann M; Berg C; Mann K; Janssen OE
    Horm Metab Res; 2005 Jan; 37(1):49-52. PubMed ID: 15702440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
    Wysocki PJ; Wierusz-Wysocka B
    Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome: are we at risk?
    Paudel B
    Nepal Med Coll J; 2007 Sep; 9(3):204-11. PubMed ID: 18092442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
    Kintzel PE; Chase SL; Schultz LM; O'Rourke TJ
    Pharmacotherapy; 2008 Dec; 28(12):1511-22. PubMed ID: 19025432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
    Pawelczyk L; Spaczynski RZ; Banaszewska B; Duleba AJ
    Eur J Obstet Gynecol Reprod Biol; 2004 Apr; 113(2):209-13. PubMed ID: 15063962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review for clinicians: Prostate cancer and the antineoplastic properties of metformin.
    Hankinson SJ; Fam M; Patel NN
    Urol Oncol; 2017 Jan; 35(1):21-29. PubMed ID: 27836248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Drug treatment of insulin resistance].
    Tenoutasse S
    Rev Med Brux; 2009; 30(2):126-8. PubMed ID: 19517913
    [No Abstract]   [Full Text] [Related]  

  • 12. Type 2 diabetes: a protective factor for prostate cancer? An overview of proposed mechanisms.
    Rastmanesh R; Hejazi J; Marotta F; Hara N
    Clin Genitourin Cancer; 2014 Jun; 12(3):143-8. PubMed ID: 24513117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome after hormone-modifying therapy: risks associated with antineoplastic therapy.
    Redig AJ; Munshi HG
    Oncology (Williston Park); 2010 Aug; 24(9):839-44. PubMed ID: 20923040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
    Chazova I; Almazov VA; Shlyakhto E
    Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin in prostate cancer: two for the price of one.
    Clements A; Gao B; Yeap SHO; Wong MKY; Ali SS; Gurney H
    Ann Oncol; 2011 Dec; 22(12):2556-2560. PubMed ID: 21421541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effects of telmisartan, sitagliptin and metformin alone or in combination on obesity, insulin resistance, and liver and pancreas remodelling in C57BL/6 mice fed on a very high-fat diet.
    Souza-Mello V; Gregório BM; Cardoso-de-Lemos FS; de Carvalho L; Aguila MB; Mandarim-de-Lacerda CA
    Clin Sci (Lond); 2010 Jun; 119(6):239-50. PubMed ID: 20415664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of lifestyle intervention and metformin on weight management and markers of metabolic syndrome in obese adolescents.
    Harden KA; Cowan PA; Velasquez-Mieyer P; Patton SB
    J Am Acad Nurse Pract; 2007 Jul; 19(7):368-77. PubMed ID: 17680902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 'worried-well', insulin resistance and metformin therapy.
    Distiller LA; Landau S; Joffe B; Kramer B; Blacking L
    S Afr Med J; 2005 Jun; 95(6):366. PubMed ID: 16100876
    [No Abstract]   [Full Text] [Related]  

  • 19. [Use of metformin in the management of adolescents with polycystic ovary syndrome].
    Zárate A; Hernández M; Fonseca ME; Ochoa R
    Ginecol Obstet Mex; 1997 Dec; 65():504-7. PubMed ID: 9477644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implications of insulin-like growth factor-I for prostate cancer therapies.
    Kojima S; Inahara M; Suzuki H; Ichikawa T; Furuya Y
    Int J Urol; 2009 Feb; 16(2):161-7. PubMed ID: 19183230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.